Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.6K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

European urology oncology·2026
Same author

Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.

The Urologic clinics of North America·2026
Same author

NCCN Guideline Updates on Radiopharmaceutical Therapy for Prostate Cancer.

European urology focus·2026
Same author

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

The Journal of urology·2026
Same author

The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.

The oncologist·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
Same journal

With great cost comes great responsibility: who will own the rising costs of bladder cancer care?

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).

James A Eastham1, Daniel A Barocas2, Carissa E Chu3

  • 1Memorial Sloan Kettering Cancer Center, New York, New York.

The Journal of Urology
|April 16, 2026
PubMed
Summary
This summary is machine-generated.

The American Urological Association updated its 2022 clinical practice guideline for localized prostate cancer management. This 2026 amendment incorporates new evidence on imaging, shared decision-making, and radiation therapy for improved patient care.

Keywords:
cancerclinicalevidenceprostateprostate cancertherapy

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

2.0K

Related Experiment Videos

Last Updated: Apr 17, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

2.0K

Area of Science:

  • Urology
  • Oncology
  • Medical Guidelines

Background:

  • The American Urological Association (AUA) previously published a guideline for localized prostate cancer in 2022.
  • Continuous evaluation of medical literature is essential for guideline relevance.

Purpose of the Study:

  • To update the 2022 AUA Guideline on the evaluation and management of clinically localized prostate cancer.
  • To incorporate new evidence and provide a revised clinical framework.

Main Methods:

  • A comprehensive literature review was conducted in 2025, examining studies published between July 1, 2021, and December 5, 2024.
  • 29 studies were reviewed for full-text inclusion, along with 8 studies on artificial intelligence in disease management.
  • Guideline statements were updated based on the evidence and consensus from the expert panel.

Main Results:

  • The updated guideline provides evidence- and consensus-based statements for localized prostate cancer.
  • Key updates include revised recommendations on imaging modalities.
  • New information on shared decision-making (SDM) and disease management strategies are incorporated.

Conclusions:

  • This 2026 Guideline Amendment offers revised insights into localized prostate cancer evaluation and management.
  • Specific updates address imaging, shared decision-making, radiation treatment, and disease management.
  • Ongoing review is necessary due to the rapid evolution of diagnostic and treatment options.